758 GLIMMER-01: phase 1/2 trial of a first-in-class bi-sialidase (E-602) in combination with cemiplimab in patients with PD-(L)1-resistant solid tumors

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Regular and Young Investigator Award Abstracts

Topics

Computer Science

Artificial Intelligence

Physics

Medicine

Quantum Mechanics

Show all topics

DOI

10.1136/jitc-2024-sitc2024.0758

License

CC-BY-NC

Other Formats

PDF